Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Plerixafor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 16/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.93 |
| ▸ | CCR2 | P41597 | 1/20 | 0.93 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.93 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Plerixafor SCHEMBL414153 | 0.98 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7612104 | 0.98 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL6889125 | 0.98 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7610931 | 0.98 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL5680189 | 0.96 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL5611617 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL29490414 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL19038 | 0.96 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7474513 | 0.95 | CXCR4 (0.93) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL1259171 | 0.95 | CXCR4 (0.90) | CXCR4HRH3MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157994-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4LIVING BIOTECH (FR) | 2023-05-25 | — | — | US | claimed |
| EP-4146195-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4Living Biotech (FR) | 2023-03-15 | — | — | EP | claimed |
| WO-2021224356-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4LIVING BIOTECH (FR) | 2021-11-11 | — | — | WO | claimed |
| EP-3906922-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4Living Biotech (FR) | 2021-11-10 | — | — | EP | claimed |
| US-20200323883-A1 | METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN, INC. (US) | 2020-10-15 | — | — | US | claimed |
| EP-3613435-A1 | CHEMOKINE RECEPTOR CXCR4 INHIBITORS FOR TREATING AND/OR PREVENTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | UNIVERSITE DE BORDEAUX (FR) | 2020-02-26 | — | — | EP | claimed |
| US-10478444-B2 | Methods and compositions for treating and preventing viral infections | ENTERIN, INC. (US) | 2019-11-19 | — | — | US | claimed |
| US-20180133230-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | ENTERIN LABORATORIES, INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20170340693-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-11-30 | — | — | US | claimed |
| EP-3229817-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | Commonwealth Scientific and Industrial Research Organisation (AU) | 2017-10-18 | — | — | EP | claimed |
| WO-2007036036-A1 | METHOD AND COMPOSITION FOR INCREASING THE ENGRAFTMENT EFFICIENCY OF STEM CELLS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2007-04-05 | — | — | WO | claimed |
| WO-2006032704-A2 | DIAGNOSTIC COMPOUNDS FOR TARGETING A CHEMOKINE RECEPTOR | GUERBET (FR) | 2006-03-30 | — | — | WO | claimed |
| US-20060035848-A1 | Broad-spectrum inhibitor of viruses in the Flaviviridae family | ZYMETX, INC. | 2006-02-16 | — | — | US | claimed |
| US-20050202005-A1 | Uses of inhibitors for the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-09-15 | — | — | US | claimed |
| EP-1009435-A4 | METHOD FOR PREVENTING HIV-1 INFECTION OF CD4?+ CELLS | PROGENICS PHARM INC (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020039993-A1 | Use of inhibitors of the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2002-04-04 | — | — | US | claimed |
| EP-1009435-A1 | METHOD FOR PREVENTING HIV-1 INFECTION OF CD4?+ CELLS | PROGENICS PHARMACEUTICALS, INC. (US) | 2000-06-21 | — | — | EP | claimed |
| WO-2000006086-A2 | USE OF INHIBITORS OF THE ACTIVATION OF CXCR4 RECEPTOR BY SDF-1 IN TREATING RHEUMATOID ARTHRITIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-02-10 | — | — | WO | claimed |
| US-5886000-A | THIAMINE DISULFIDE AND IT'S DERIVATIVES AS VIRICIDES TREATING HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNE DEFICIENCY SYNDROME; POTENTIATION | NISSUI PHARMACEUTICAL CO., LTD, (JP) | 1999-03-23 | — | — | US | claimed |
| WO-1998056421-A1 | METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS | PROGENICS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10478444-B2 | Methods and compositions for treating and preventing viral infections | STING1, IFNG, TSLP | CXCR4 1012/4885HRH3 1263/4885MEN1 2069/4885 |
| US-20180133230-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, IFNG, TSLP | CXCR4 1012/4885HRH3 1263/4885MEN1 2069/4885 |
| US-20060035848-A1 | Broad-spectrum inhibitor of viruses in the Flaviviridae family | EIF2AK2, MAVS, EFTUD2 | CXCR4 3936/4885HRH3 4598/4885MEN1 4768/4885 |
| US-20200323883-A1 | METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | STING1, TSLP, MAVS | CXCR4 1217/4885HRH3 1452/4885MEN1 2708/4885 |
| US-20170340693-A1 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST | CXCL12, CXCR4, CCR9 | CXCR4 2/4885HRH3 345/4885MEN1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.